Frontier Biotechnologies obtained approval for Aikening® (albuvirtide for injection), the first long-acting fusion inhibitor treatment for HIV, from the National Pharmaceutical Regulatory Agency of Malaysia in September 2022. Subsequently, Frontier Biotech partnered Pahang Pharmacy and participated at the Malaysian HIV Forum (My HIV Forum) on 15 - 16 October, 2022 and unveiled the availability of Aikening®.

The event was organized by the Malaysian Society for HIV Medicine, and held at the University Teknologi Mara Kampus Sungai Buloh. It was well attended by over 400 HIV experts and delegates across the various states in Malaysia.

It was a productive meeting whereby Frontier Biotech interacted with eminent HIV experts from Malaysia and raised awareness of Aikening, a new antiretroviral drug (ARV) to help in the fight against the AIDS epidemic.